FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Schroeder Blake 2. Issuer Name and Ticker or Trading Symbol AXIM BIOTECHNOLOGIES, INC. [ AXIM ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
6191 CORNERSTONE COURT, E., SUITE 114
3. Date of Earliest Transaction (MM/DD/YYYY)
2/10/2022
(Street)
SAN DIEGO, CA 92121
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Convertible Note (Convertible into Common Stock)  $0.0812  2/10/2022    J (1)    25000.0000      2/10/2022  2/10/2032  Common Stock  307692.0000  $25000.0000  307692.0000  D 
 

Explanation of Responses:
(1)  This Note bears interest at a rate of 3% per annum. At the election of the Reporting Person, all principal and accrued interest under the Note may be converted into the Issuer's common stock at a converstion price equal to the lesser of $0.08125 or 70% of the average of the two lowest closing prices of the Issuer's common stock in the ten (10) days prior to the date of conversion.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Schroeder Blake
6191 CORNERSTONE COURT, E.
SUITE 114
SAN DIEGO, CA 92121
X



Signatures
/s/ Blake Neil Schroeder 2/15/2022
**Signature of Reporting Person Date
Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Axim Biotechnologies (QB) Charts.
Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Axim Biotechnologies (QB) Charts.